A pharmaceuticals company will have to cut dramatically the price of an epilepsy drug after losing its legal action against the competition watchdog.
Flynn Pharma had previously been fined £5.2 million by the Competition and Markets Authority after the price of phenytoin sodium capsules that it sold rose by 2,600 per cent.
Pfizer, which manufactured the capsules and struck a deal with Flynn prior to the price rise, was fined a record £84.2 million as part of the same CMA decision.
In a hearing last week, Flynn asked the Competition Appeal Tribunal to suspend the CMA’s ruling that it had to decrease the price of the medicine by today because it plans to file an appeal against the watchdog’s decision.
Full Content: The Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC to Approve Exxon’s $64 Billion Deal with Pioneer Resources, Excludes
May 1, 2024 by
CPI
UK Competition Watchdog Raises Alarm Over Nvidia’s ARM Takeover
May 1, 2024 by
CPI
Sen. Klobuchar Urges Regulators to Probe Collusion in Health Care Pricing
May 1, 2024 by
CPI
Multiple States Join Tennessee’s Antitrust Lawsuit Against NCAA Over NIL Rules
May 1, 2024 by
CPI
NY AG Joins Suit Challenging NCAA’s Restrictions on Student Athlete NIL Rights
May 1, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI